New combo therapy aims to shrink deadly esophageal tumors
NCT ID NCT06531434
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This pilot study tests a two-step treatment for T4 esophageal cancer, where the tumor has spread to nearby organs. First, patients receive up to 8 cycles of chemotherapy with docetaxel, cisplatin, and fluorouracil. If the tumor shrinks enough, they then get a lower dose of radiation combined with cisplatin. The goal is to see if this approach reduces the risk of a hole forming in the esophagus (perforation) and improves response and survival. The study enrolls 22 adults aged 18-70 with good organ function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Docetaxel, Cisplatin, fluorouracil, and radiation
- What this could lead to
- If successful, this approach could offer a safer and more effective treatment strategy for advanced esophageal cancer, potentially improving survival and reducing complications.
- What could go wrong
- This is a small, early-phase pilot study with only 22 participants, so results may not apply broadly. The treatment involves strong chemotherapy and radiation, which carry risks like infection, bleeding, and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER TNM STAGING PRIMARY TUMOR (T) T4 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cheng Kung University Hospital
RECRUITINGTainan, Taiwan, 704302, Taiwan